Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shin, D. M.
Right arrow Articles by Hong, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shin, D. M.
Right arrow Articles by Hong, W. K.
Clinical Cancer Research Vol. 7, 1204-1213, May 2001
© 2001 American Association for Cancer Research

Clinical Trials

Epidermal Growth Factor Receptor-targeted Therapy with C225 and Cisplatin in Patients with Head and Neck Cancer1

Dong M. Shin2, Nicholas J. Donato, Roman Perez-Soler3, Hyung Ju C. Shin, Ji Y. Wu, Peter Zhang, Kristie Lawhorn, Fadlo R. Khuri, Bonnie S. Glisson, Jeffrey Myers, Gary Clayman, David Pfister, John Falcey, Harlan Waksal, John Mendelsohn and Waun Ki Hong

Departments of Thoracic/Head and Neck Medical Oncology [D. M. S., R. P-S., P. Z., K. L., F. R. K., B. S. G., W. K. H.], Bioimmunotherapy [N. J. D., J. Y. W.], Pathology [H. J. C. S.], Head and Neck Surgery [J. My., G. C.], and Experimental Therapeutics [J. Me.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [D. P.]; and ImClone Systems, Inc., Somerville, New Jersey 08876 [J. F., H. W.]

C225, a human-mouse chimerized monoclonal antibody directed against the epidermal growth factor receptor (EGFr), has a synergistic effect with cisplatin in xenograft models. To determine the tumor EGFr saturation dose with C225 and the fate of infused C225, we conducted a Phase Ib study with C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck. Using tumor samples, we assessed tumor EGFr saturation by antibody using immunohistochemistry studies, the EGFr tyrosine kinase assay, and detection of the EGFr/C225 complex formation by immunoblot. Potential candidates were screened for EGFr expression in their tumors, and 12 patients who had high levels of EGFr expression and tumors easily accessible for repeated biopsies (pretherapy, 24 h after first C225 infusion, 24 h before third C225 infusion) were entered at three different dose levels of C225 with a fixed dose of cisplatin. The median value of tumor EGFr saturation increased to 95% at the higher dose levels. EGFr tyrosine kinase activity was significantly reduced after C225 infusion, and EGFr/C225 complexes were also detected at higher doses of C225. The loading dose of C225 at 400 mg/m2 with a maintenance dose at 250 mg/m2 achieved a high percentage of saturation of EGFr in tumor tissue, and these doses were recommended for Phases II or III clinical trials. Six (67%) of nine evaluable patients achieved major responses, including two (22%) complete responses. Mild to moderate degrees of allergic reaction and folliculitis-like skin reactions were demonstrated. We conclude that infused C225 binds and significantly saturates tumor EGFr, which may render a high degree of antitumor activity, and provides a novel mechanism for targeting cancer therapy for patients who have EGFr expression in their tumors.




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
N. L. Dirks, A. Nolting, A. Kovar, and B. Meibohm
Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck
J. Clin. Pharmacol., March 1, 2008; 48(3): 267 - 278.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist, January 1, 2008; 13(1): 25 - 38.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Harari, G. W. Allen, and J. A. Bonner
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
J. Clin. Oncol., September 10, 2007; 25(26): 4057 - 4065.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Q. Zhang, N. E. Bhola, V. W. Y. Lui, D. R. Siwak, S. M. Thomas, C. T. Gubish, J. M. Siegfried, G. B. Mills, D. Shin, and J. R. Grandis
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer
Mol. Cancer Ther., April 1, 2007; 6(4): 1414 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Fracasso, H. Burris III, M. A. Arquette, R. Govindan, F. Gao, L. P. Wright, S. A. Goodner, F. A. Greco, S. F. Jones, N. Willcut, et al.
A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Clin. Cancer Res., February 1, 2007; 13(3): 986 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. R. Tan, D. F. Moore, M. Hidalgo, J. H. Doroshow, E. A. Poplin, S. Goodin, D. Mauro, and E. H. Rubin
Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors
Clin. Cancer Res., November 1, 2006; 12(21): 6517 - 6522.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen
Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
M. J. Worsham, K. M. Chen, N. Tiwari, G. Pals, J. P. Schouten, S. Sethi, and M. S. Benninger
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 409 - 415.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, Y. B. Su, D. H. Kraus, S. L. Wolden, E. Lis, T. B. Aliff, A. J. Zahalsky, S. Lake, M. N. Needle, A. R. Shaha, et al.
Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm
J. Clin. Oncol., March 1, 2006; 24(7): 1072 - 1078.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. A Frieze and J. S McCune
Current Status of Cetuximab for the Treatment of Patients with Solid Tumors
Ann. Pharmacother., February 1, 2006; 40(2): 241 - 250.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere
Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
J. Clin. Oncol., December 1, 2005; 23(34): 8646 - 8654.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Herbst, M. Arquette, D. M. Shin, K. Dicke, E. E. Vokes, N. Azarnia, W. K. Hong, and M. S. Kies
Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., August 20, 2005; 23(24): 5578 - 5587.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga, J. M. Trigo, J. Bourhis, J. Tortochaux, H. Cortes-Funes, R. Hitt, P. Gascon, N. Amellal, A. Harstrick, and A. Eckardt
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., August 20, 2005; 23(24): 5568 - 5577.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. K. Gibson, Y. Li, B. Murphy, M. H.A. Hussain, R. C. DeConti, J. Ensley, and A. A. Forastiere
Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group
J. Clin. Oncol., May 20, 2005; 23(15): 3562 - 3567.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. T.C. Chan, M.-M. Hsu, B. C. Goh, E. P. Hui, T.-W. Liu, M. J. Millward, R.-L. Hong, J. Whang-Peng, B. B.Y. Ma, K. F. To, et al.
Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
J. Clin. Oncol., May 20, 2005; 23(15): 3568 - 3576.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P M Harari
Epidermal growth factor receptor inhibition strategies in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. F. Stewart, M. Leggas, J. D. Schuetz, J. C. Panetta, P. J. Cheshire, J. Peterson, N. Daw, J. J. Jenkins III, R. Gilbertson, G. S. Germain, et al.
Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice
Cancer Res., October 15, 2004; 64(20): 7491 - 7499.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
D. Atkins, K.-A. Reiffen, C. L. Tegtmeier, H. Winther, M. S. Bonato, and S. Storkel
Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues: Variation in Staining Intensity Due to Choice of Fixative and Storage Time of Tissue Sections
J. Histochem. Cytochem., July 1, 2004; 52(7): 893 - 901.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarwala, and L. L. Siu
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
J. Clin. Oncol., January 1, 2004; 22(1): 77 - 85.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn and J. Baselga
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
H. E. Gonzalez, M. Gujrati, M. Frederick, Y. Henderson, J. Arumugam, P. W. Spring, K. Mitsudo, H.-W. Kim, and G. L. Clayman
Identification of 9 Genes Differentially Expressed in Head and Neck Squamous Cell Carcinoma
Arch Otolaryngol Head Neck Surg, July 1, 2003; 129(7): 754 - 759.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. N. Malik, L. L. Siu, E. K. Rowinsky, L. deGraffenried, L. A. Hammond, J. Rizzo, S. Bacus, M. G. Brattain, J. I. Kreisberg, and M. Hidalgo
Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients
Clin. Cancer Res., July 1, 2003; 9(7): 2478 - 2486.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Grunwald and M. Hidalgo
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Sriuranpong, J. I. Park, P. Amornphimoltham, V. Patel, B. D. Nelkin, and J. S. Gutkind
Epidermal Growth Factor Receptor-independent Constitutive Activation of STAT3 in Head and Neck Squamous Cell Carcinoma Is Mediated by the Autocrine/Paracrine Stimulation of the Interleukin 6/gp130 Cytokine System
Cancer Res., June 1, 2003; 63(11): 2948 - 2956.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. W. Cohen, F. Rosen, W. M. Stadler, W. Recant, K. Stenson, D. Huo, and E. E. Vokes
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., May 15, 2003; 21(10): 1980 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
P. L. Friedlander
The Use of Genetic Markers in the Clinical Care of Patients With Head and Neck Cancer
Arch Otolaryngol Head Neck Surg, March 1, 2003; 129(3): 363 - 366.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Ronnstrand, A. Blaukat, K. M. Beeh, F. Oesch, B. Fischer, R. Buhl, et al.
Characterization of c-kit Expression in Small Cell Lung Cancer: Prognostic and Therapeutic Implications
Clin. Cancer Res., January 1, 2003; 9(1): 188 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. K. Ang, B. A. Berkey, X. Tu, H.-Z. Zhang, R. Katz, E. H. Hammond, K. K. Fu, and L. Milas
Impact of Epidermal Growth Factor Receptor Expression on Survival and Pattern of Relapse in Patients with Advanced Head and Neck Carcinoma
Cancer Res., December 15, 2002; 62(24): 7350 - 7356.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
J. S de Bono and E. K Rowinsky
Therapeutics targeting signal transduction for patients with colorectal carcinoma
Br. Med. Bull., December 1, 2002; 64(1): 227 - 254.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Li, C. Ye, C. Feng, F. Riedel, X. Liu, Q. Zeng, and J. R. Grandis
Enhanced Antiangiogenic Therapy of Squamous Cell Carcinoma by Combined Endostatin and Epidermal Growth Factor Receptor-Antisense Therapy
Clin. Cancer Res., November 1, 2002; 8(11): 3570 - 3578.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. D. Fox, B. Higgins, K. M. Maiese, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, and D. B. Agus
Antibody to Vascular Endothelial Growth Factor Slows Growth of an Androgen-independent Xenograft Model of Prostate Cancer
Clin. Cancer Res., October 1, 2002; 8(10): 3226 - 3231.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn
Targeting the Epidermal Growth Factor Receptor for Cancer Therapy
J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13.
[Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
T. Kijima, H. Niwa, R. A. Steinman, S. D. Drenning, W. E. Gooding, A. L. Wentzel, S. Xi, and J. R. Grandis
STAT3 Activation Abrogates Growth Factor Dependence and Contributes to Head and Neck Squamous Cell Carcinoma Tumor Growth in Vivo
Cell Growth Differ., August 1, 2002; 13(8): 355 - 362.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Rolf. F. Barth, W. Yang, D. M. Adams, J. H. Rotaru, S. Shukla, M. Sekido, W. Tjarks, R. A. Fenstermaker, M. Ciesielski, M. M. Nawrocky, et al.
Molecular Targeting of the Epidermal Growth Factor Receptor for Neutron Capture Therapy of Gliomas
Cancer Res., June 1, 2002; 62(11): 3159 - 3166.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Casanova, F. Larcher, B. Casanova, R. Murillas, M. J. Fernandez-Acenero, C. Villanueva, J. Martinez-Palacio, A. Ullrich, C. J. Conti, and J. L. Jorcano
A Critical Role for ras-mediated, Epidermal Growth Factor Receptor-dependent Angiogenesis in Mouse Skin Carcinogenesis
Cancer Res., June 1, 2002; 62(12): 3402 - 3407.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Prewett, A. T. Hooper, R. Bassi, L. M. Ellis, H. W. Waksal, and D. J. Hicklin
Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts
Clin. Cancer Res., May 1, 2002; 8(5): 994 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. B. Hassan and V. M. Macaulay
The insulin-like growth factor system as a therapeutic target in colorectal cancer
Ann. Onc., March 1, 2002; 13(3): 349 - 356.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen and E. E. Vokes
Searching for a Standard
J. Clin. Oncol., January 15, 2002; 20(2): 359 - 361.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Ciardiello and G. Tortora
A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor
Clin. Cancer Res., October 1, 2001; 7(10): 2958 - 2970.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.